Bristol Myers to accumulate cell remedy associate 2seventy bio in $286M all-cash deal (BMY:NYSE)

2seventy bio (NASDAQ:TSVT) shares popped almost 4% premarket on Tuesday after it entered a deal to be acquired by Bristol Myers Squibb (NYSE:BMY) in an ~$286M all-cash transaction (or $102M web of estimated money).

Bristol Myers Squibb (NYSE:BMY) will